Motor abnormalities in first-episode psychosis patients and long-term psychosocial functioning

Schizophrenia Research

Volumn 200, Issue , 2018, Pages 97-103

  Cuesta, Manuel J ^a,c   García de Jalón, Elena ^b,c   Campos, M Sol ^d   Moreno Izco, Lucía ^a,c   Lorente Omeñaca, Ruth ^a,c   Sánchez Torres, Ana M ^a,c   Peralta, Víctor ^b,c  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b Mental Health Department of Servicio Navarro de Salud   (Spain)

^c IdiSNA Navarra Institute for Health Research   (Spain)

^d Servicio de Salud Mental de La Rioja   (Spain)

Author keywords

Abnormal movements; Catatonia; Extrapyramidal signs; Neurological assessment; Neurological soft signs; Psychosocial functioning; Schizophrenia

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADULT; AGED; AKATHISIA; ARTICLE; CATATONIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DELUSIONAL DISORDER; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DSM-5; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PARKINSONISM; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SOCIAL PSYCHOLOGY; STATISTICAL MODEL; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; PSYCHOLOGY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CATATONIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PROGNOSIS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 85053565323     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2017.08.050     Document Type: Article

References (56)

1. Aas, I.H., Guidelines for rating Global Assessment of Functioning (GAF). Ann. Gen. Psychiatry, 20(10), 2011, 2.
2. Amminger, G.P., Henry, L.P., Harrigan, S.M., Harris, M.G., Alvarez-Jimenez, M., Herrman, H., Jackson, H.J., McGorry, P.D., Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr. Res. 131:1–3 (2011), 112–119.
3. Andreasen, N.C., Flaum, M., Arndt, S., The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 49:8 (1992), 615–623.
4. Austin, S.F., Mors, O., Secher, R.G., Hjorthøj, C.R., Albert, N., Bertelsen, M., Jensen, H., Jeppesen, P., Petersen, L., Randers, L., Thorup, A., Nordentoft, M., Predictors of recovery in first episode psychosis: the OPUS cohort at 10 year follow-up. Schizophr. Res. 150:1 (2013), 163–168.
5. Bachmann, S., Degen, C., Geider, F.J., Schröder, J., Neurological soft signs in the clinical course of schizophrenia: results of a meta-analysis. Front. Psych., 23(5), 2014, 185.
6. Barnes, T.R., A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989), 672–676.
7. Bland, R.C., Predicting the outcome in schizophrenia. Can. J. Psychiatr. 27 (1982), 52–62.
8. Bowie, C.R., Harvey, P.D., Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North Am. 28:3 (2005), 613–633 (626).
9. Bowie, C.R., Reichenberg, A., Patterson, T.L., Heaton, R.K., Harvey, P.D., Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 163 (2006), 418–425.
10. Buchanan, R.W., Heinrichs, D.W., The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res. 27 (1989), 335–350.
11. Burton, B.K., Hjorthøj, C., Jepsen, J.R., Thorup, A., Nordentoft, M., Plessen, K.J., Research review: do motor deficits during development represent an endophenotype for schizophrenia? A meta-analysis. J. Child Psychol. Psychiatry 57:4 (2016), 446–456.
12. Burton, B.K., Thorup, A.A., Jepsen, J.R., Poulsen, G., Ellersgaard, D., Spang, K.S., Christiani, C.J., Hemager, N., Gantriis, D., Greve, A., Mors, O., Nordentoft, M., Plessen, K.J., Impairments of motor function among children with a familial risk of schizophrenia or bipolar disorder at 7 years old in Denmark: an observational cohort study. Lancet Psychiatry 4 (2017), 400–408.
13. Chan, R.C., Geng, F.L., Lui, S.S., Wang, Y., Ho, K.K., Hung, K.S., Gur, R.E., Gur, R.C., Cheung, E.F., Course of neurological soft signs in first-episode schizophrenia: relationship with negative symptoms and cognitive performances. Sci Rep, 8(5), 2015, 11053.
14. Chen, E.Y., Kwok, C.L., Au, J.W., Chen, R.Y., Lau, B.S., Progressive deterioration of soft neurological signs in chronic schizophrenic patients. Acta Psychiatr. Scand. 102:5 (2000), 342–349.
15. Cuesta, M.J., Jalón, E.G., Campos, M.S., Peralta, V., Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br. J. Psychiatry 194:5 (2009), 439–445.
16. Cuesta, M.J., Sánchez-Torres, A.M., de Jalón, E.G., Campos, M.S., Ibáñez, B., Moreno-Izco, L., Peralta, V., Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study. Schizophr. Bull. 40:5 (2014), 1164–1173.
17. Filatova, S., Koivumaa-Honkanen, H., Hirvonen, N., Freeman, A., Ivandic, I., Hurtig, T., Khandaker, G.M., Jones, P.B., Moilanen, K., Miettunen, J., Early motor developmental milestones and schizophrenia: a systematic review and meta-analysis. Schizophr. Res., 2017 (Jan 25. pii: S0920-9964(17)30042-7).
18. Francis, A., Fink, M., Appiani, F., Bertelsen, A., Bolwig, T.G., Bräunig, P., Caroff, S.N., Carroll, B.T., Cavanna, A.E., Cohen, D., Cottencin, O., Cuesta, M.J., Daniels, J., Dhossche, D., Fricchione, G.L., Gazdag, G., Ghaziuddin, N., Healy, D., Klein, D., Krüger, S., Lee, J.W., Mann, S.C., Mazurek, M., McCall, W.V., McDaniel, W.W., Northoff, G., Peralta, V., Petrides, G., Rosebush, P., Rummans, T.A., Shorter, E., Suzuki, K., Thomas, P., Vaiva, G., Wachtel, L., Catatonia in diagnostic and statistical manual of mental disorders, fifth edition. J ECT 26:4 (2010), 246–247 (Dec).
19. Gardner, D.M., Murphy, A.L., O'Donnell, H., Centorrino, F., Baldessarini, R.J., International consensus study of antipsychotic dosing. Am. J. Psychiatry 167:6 (2010), 686–693.
20. Green, M.F., Kern, R.S., Braff, D.L., Mintz, J., Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr. Bull. 26 (2000), 119–136.
21. Guy, W., Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. 1976, National Institute of Mental Health, Washington, DC, 217–222.
22. Haro, J.M., Novick, D., Suarez, D., Ochoa, S., Roca, M., Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32:5 (2008), 1287–1292 (Jul 1).
23. Harrison, G., Hopper, K., Craig, T., Laska, E., Siegel, C., Wanderling, J., Dube, K.C., Ganev, K., Giel, R., an der Heiden, W., Holmberg, S.K., Janca, A., Lee, P.W., León, C.A., Malhotra, S., Marsella, A.J., Nakane, Y., Sartorius, N., Shen, Y., Skoda, C., Thara, R., Tsirkin, S.J., Varma, V.K., Walsh, D., Wiersma, D., Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br. J. Psychiatry 178 (2001), 506–517 (Jun).
24. Harvey, P.D., Velligan, D.I., Bellack, A.S., Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophr. Bull. 33:5 (2007), 1138–1148 (Sep).
25. Jääskeläinen, E., Juola, P., Hirvonen, N., McGrath, J.J., Saha, S., Isohanni, M., Veijola, J., Miettunen, J., A systematic review and meta-analysis of recovery in schizophrenia. Schizophr. Bull. 39:6 (2013), 1296–1306 (Nov).
26. Janca, A., Kastrup, M., Katschnig, H., López-Ibor, J.J. Jr., Mezzich, J.E., Sartorius, N., The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Soc. Psychiatry Psychiatr. Epidemiol. 31:6 (1996), 349–354 (Nov).
27. Jonsson, S.A.T., Jonsson, H., Outcome in untreated schizophrenia: a search for symptoms and traits with prognostic meaning in patients admitted to a mental hospital in the preneuroleptic era. Acta Psychiatr. Scand. 85 (1992), 313–320.
28. Koning, J.P., Tenback, D.E., van Os, J., Aleman, A., Kahn, R.S., van Harten, P.N., Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr. Bull. 36:4 (2010), 723–731 (Jul).
29. Leung, W.W., Bowie, C.R., Harvey, P.D., Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: a cross-sectional study. J. Int. Neuropsychol. Soc. 14:3 (2008), 479–488 (May).
30. Mas-Expósito, L., Amador-Campos, J.A., Gómez-Benito, J., Lalucat-Jo, L., The World Health Organization Short Disability Assessment Schedule: a validation study in patients with schizophrenia. Compr. Psychiatry. 53:2 (2012), 208–216 (Feb).
31. Minichino, A., Francesconi, M., Carrión, R.E., Delle Chiaie, R., Bevilacqua, A., Parisi, M., Rullo, S., Bersani, F.S., Biondi, M., Cadenhead, K., From neurological soft signs to functional outcome in young individuals in treatment with secondary services for non-psychotic disorders: a path analysis. Psychol. Med. 47:7 (2017), 1192–1203 (May).
32. Mittal, V.A., Jalbrzikowski, M., Daley, M., Roman, C., Bearden, C.E., Cannon, T.D., Abnormal movements are associated with poor psychosocial functioning in adolescents at high risk for psychosis. Schizophr. Res. 130:1–3 (2011), 164–169 (Aug).
33. Niemi, L.T., Suvisaari, J.M., Tuulio-Henriksson, A., Lönnqvist, J.K., Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr. Res. 60:2-3 (2003), 239–258 (Apr 1).
34. Obeso, J.A., Rodriguez-Oroz, M.C., Stamelou, M., Bhatia, K.P., Burn, D.J., The expanding universe of disorders of the basal ganglia. Lancet 384:9942 (2014), 523–531 (Aug 9).
35. Patterson, T.L., Mausbach, B.T., Measurement of functional capacity: a new approach to understanding functional differences and real-world behavioral adaptation in those with mental illness. Annu. Rev. Clin. Psychol. 6 (2010), 139–154.
36. Peralta, V., Cuesta, M.J., The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine. Prim. Care Companion J. Clin. Psychiatry, 12(2), 2010 (pii: PCC.09m00799).
37. Peralta, V., Cuesta, M.J., Motor abnormalities: from neurodevelopmental to neurodegenerative through “functional” (neuro)psychiatric disorders. Schizophr. Bull., 2017 doi.org/10.1093/schbul/sbx089 (Published online 20 July 2017).
38. Peralta, V., Moreno-Izco, L., Sanchez-Torres, A., García de Jalón, E., Campos, M.S., Cuesta, M.J., Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. Schizophr. Bull. 40 (2014), 214–224.
39. Perkins, D.O., Leserman, J., Jarskog, L.F., Graham, K., Kazmer, J., Lieberman, J.A., Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr. Res. 44:1 (2000), 1–10 (Jul 7).
40. Randall, J.R., Vokey, S., Loewen, H., Martens, P.J., Brownell, M., Katz, A., Nickel, N.C., Burland, E., Chateau, D., A systematic review of the effect of early interventions for psychosis on the usage of inpatient services. Schizophr. Bull. 41:6 (2015), 1379–1386 (Nov).
41. Rogers, D., The motor disorders of severe psychiatric illness: a conflict of paradigms. Br. J. Psychiatry 147 (1985), 221–232.
42. Rosa, A.R., Sánchez-Moreno, J., Martínez-Aran, A., Salamero, M., Torrent, C., Reinares, M., Comes, M., Colom, F., Van Riel, W., Ayuso-Mateos, J.L., Kapczinski, F., Vieta, E., Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin. Pract. Epidemiol. Ment. Health 7 (2007), 3–5 (Jun).
43. Sánchez-Torres, A.M., Elosúa, M.R., Lorente-Omeñaca, R., Moreno-Izco, L., Peralta, V., Cuesta, M.J., The Cognitive Assessment Interview: a comparative study in first episode and chronic patients with psychosis. Schizophr. Res. 178:1-3 (2016), 80–85 (Dec).
44. Schennach-Wolff, R., Jäger, M., Seemüller, F., Obermeier, M., Messer, T., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L.G., Gaebel, W., Huff, W., Heuser, I., Maier, W., Lemke, M.R., Rüther, E., Buchkremer, G., Gastpar, M., Möller, H.J., Riedel, M., Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr. Res. 113:2-3 (2009), 210–217 (Sep).
45. Schoenbaum, M., Sutherland, J.M., Chappel, A., Azrin, S., Goldstein, A.B., Rupp, A., Heinssen, R.K., Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States. Schizophr. Bull., 2017 (Apr 7).
46. Sienaert, P., Dhossche, D.M., Vancampfort, D., De Hert, M., Gazdag, G., A clinical review of the treatment of catatonia. Front. Psych., 5(181), 2014 (Dec 9).
47. Simpson, G., Angus, J., A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 (1970), S11–S19.
48. Strauss, J.S., Carpenter, W.T. Jr., The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia. Arch. Gen. Psychiatry 31:1 (1974), 37–42 (Jul).
49. Strauss, J.S., Carpenter, W.T. Jr., Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. Arch. Gen. Psychiatry 34:2 (1977), 159–163 (Feb).
50. van Os, J., Fahy, T.A., Jones, P., Harvey, I., Sham, P., Lewis, S., Bebbington, P., Toones, B., Williams, M., Murray, R., Psychopathological syndromes in the functional psychoses: associations with course and outcome. Psychol. Med. 26:1 (1996), 161–176 (Jan).
51. Verma, S., Subramaniam, M., Abdin, E., Poon, L.Y., Chong, S.A., Symptomatic and functional remission in patients with first-episode psychosis. Acta Psychiatr. Scand. 126:4 (2012), 282–289 (Oct).
52. Walker, E.F., Savoie, T., David, D., Motor precursors of schizophrenia. Schizophr. Bull. 20:3 (1994), 441–451.
53. Whitty, P.F., Owoeye, O., Waddington, J.L., Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr. Bull. 35:2 (2009), 415–424 (Mar).
54. Woods, S.W., Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64:6 (2003), 663–667 (Jun).
55. World Health Organization, Schizophrenia and Public Health. 1998, WHO, Geneva.
56. Yarden, P.E., Discipio, W.J., Abnormal movements and prognosis in schizophrenia. Am. J. Psychiatry. 128:3 (1971), 317–323 (Sep).